Kappa Light Chain antibody
Goat anti Human Kappa Light Chain:FITC
- Product Type
- Polyclonal Antibody
- Isotype
- Polyclonal IgG
- Specificity
- Kappa Light Chain
Goat anti Human Kappa Light Chain antibody recognizes human kappa light chains. This antibody has been cross absorbed against pooled human myeloma proteins with lambda light chains. |
- Target Species
- Human
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Antiserum Preparation
- Antisera to human kappa chains were raised by repeated immunisation of goats with purified antigen. Purified IgG was prepared from whole serum by affinity chromatography.
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- <0.1% Sodium Azide (NaN3)
- Immunogen
- Human kappa light chain
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Max Ex/Em
-
Fluorophore Excitation Max (nm) Emission Max (nm) FITC 490 525 - Regulatory
- For research purposes only
- Guarantee
- Guaranteed for 12 months from the date of despatch or until the date of expiry, whichever comes first. Please see label for expiry date.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Application Name | Verified | Min Dilution | Max Dilution |
---|---|---|---|
Flow Cytometry | Neat | 1/10 | |
Immunofluorescence | Neat | 1/10 | |
Immunohistology - Frozen |
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul
Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
---|---|---|---|---|---|---|---|
Human Seroblock | BUF070A | F | 50 Test | Log in | |||
List Price | Your Price | ||||||
Log in | |||||||
Description | Human Seroblock | ||||||
Human Seroblock | BUF070B | F | 200 Test | Log in | |||
List Price | Your Price | ||||||
Log in | |||||||
Description | Human Seroblock |
References for Kappa Light Chain antibody
-
Veisman, I. et al. (2021) Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study.
J Clin Med. 10 (18): 4265. -
Ungar, B. et al. (2021) Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.
J Crohns Colitis. 15 (10): 1707-19. -
Levartovsky, A. et al. (2023) Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
Biomedicines. 11 (6): 1553.
- RRID
- AB_1102713
- UniProt
- P01834
- Entrez Gene
- IGKC
- GO Terms
- GO:0005515 protein binding
- GO:0003823 antigen binding
- GO:0005576 extracellular region
- GO:0006958 complement activation, classical pathway
- GO:0045087 innate immune response
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
View all Anti-Human ProductsAlways be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up